The study led by Annette Von Drygalski, M.D., third year internal medicine resident, and Richard H. Aster M.D., professor of medicine at the Medical College, and senior investigator at the Blood Research Institute, will appear in the March 1, 2007, edition of New England Journal of Medicine.
Patients suspected of having thrombocytopenia, or low blood platelet count often associated with bleeding, can be tested for a special type of antibody to see if it is related to medications. For this study, the researchers obtained clinical information on 29 patients who tested positive for vancomycin-dependent platelet antibodies. The patients were seen at major U.S. hospitals.
"We found a close correlation between exposure to vancomycin, development of a vancomycin-dependent antibody, and the onset of severe thrombocytopenia accompanied by serious bleeding in most cases," Says Dr. Aster. "Three of the 29 cases described ended fatally. Serious bleeding appears to have contributed to these outcomes."
It is not widely recognized that vancomycin can cause thrombocytopenia. For that reason, the medication was continued in 15 of the 29 patients while other possible causes for the low platelet count were investigated, according to Dr. Aster. None of these patients had a rise in the platelet count until the vancomycin was discontinued and an alternative antibiotic started. The vancomycin was stopped early in the remaining 14 patients because it was suspected to be the cause of the thrombocytopenia. The platelet count of these patients rose to normal shortly thereafter.
In a separate study, the researchers found that 25 patients given vancomycin who did not develop thrombocytopenia did not develop antibodies.
"Vancomycin has been in widespread use for more than 25 years and can be a life-saving medication when used in the appropriate context," says Dr. Aster. Since only a small fraction of patients given vancomycin produce antibodies that cause thrombocytopenia, the findings should have no impact on the clinical use of vancomycin."
"Instead," he says, "clinicians administering vancomycin should be alert to the fact that it can cause severe immune thrombocytopenia and have their patient seen by a hematology consultant if they develop a low platelet count while under treatment with the drug. If there's a question, the physician should substitute another antibiotic for vancomycin for a few days to see if the platelet count improves."
Dr. Aster's team will continue to study patients with vancomycin-induced immune thrombocytopenia as they are encountered.
"The real lessons, though, will be learning more about how drugs such as vancomycin trigger the production of antibodies that destroy red and white blood cells in addition to platelets. We also hope to find out how the drugs cause this type of antibody to bind to blood cells and cause their destruction. A longer-term goal is to develop ways to identify environmental and genetic factors that predispose individuals to experience this type of drug hypersensitivity reaction," says Dr. Aster.
Toranj Marphetia | EurekAlert!
New study first to predict which oil and gas wells are leaking methane
21.12.2018 | University of Vermont
Droughts boost emissions as hydropower dries up
21.12.2018 | Stanford's School of Earth, Energy & Environmental Sciences
World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles
The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.
Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.
In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...
Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.
It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:
The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.
One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...
Just in time for Christmas, a Mars-analogue mission in Morocco, coordinated by the Robotics Innovation Center of the German Research Center for Artificial Intelligence (DFKI) as part of the SRC project FACILITATORS, has been successfully completed. SRC, the Strategic Research Cluster on Space Robotics Technologies, is a program of the European Union to support research and development in space technologies. From mid-November to mid-December 2018, a team of more than 30 scientists from 11 countries tested technologies for future exploration of Mars and Moon in the desert of the Maghreb state.
Close to the border with Algeria, the Erfoud region in Morocco – known to tourists for its impressive sand dunes – offered ideal conditions for the four-week...
16.01.2019 | Event News
14.01.2019 | Event News
12.12.2018 | Event News
17.01.2019 | Physics and Astronomy
17.01.2019 | Materials Sciences
17.01.2019 | Information Technology